MS Views and News Be empowered with MS views and news. To receive The MS BEACON e-Newsletter, CLICK HERE - -

Visit our MS learning channel on YouTube, which provides hundreds of MS educational videos presented by MS Experts from across the USA. Archived here: www.youtube.com/msviewsandnews -- Also please visit our Social media platforms: Facebook, Twitter, and Instagram . Each providing important information for the MS community. Furthermore, scroll down the left side of this blog to learn from the resources and links.

Disclaimer: 'MS Views and News' DOES NOT endorse any products or services found on this blog. It is up to you to seek advice from your healthcare provider. The intent of this blog is to provide information on various medical conditions, medications, treatments, for your personal knowledge and to keep you informed of current health-related issues. It is not a substitute for the advice of your physician. Should you or your family members have any specific medical problem, seek medical care promptly.

~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~


Wednesday, July 19, 2017

Fighting in Court Over MS Generics


                                                                  
  
Click here to receive MS news via e-mail


Biogen is a big pharmaceutical company that produces a half-dozen MS drugs. Among them are TysabriAvonex and Tecfidera. And Biogenis doing all it can to protect its turf, particularly when it comes to its best seller, Tecfidera.
Last month the company filed lawsuits against several pharmaceutical companies that are trying to develop generic versions of Tecfidera. According to an article in the Boston Business Journal, in the five days between June 26-30 Biogen filed 26 patent-infringement lawsuits in federal court against several competitors, including Mylan Pharmaceuticals and Sandoz.
The patents involved in the lawsuits expire over the next 10 years. In its suit against Sandoz, Biogen claims  it “will suffer substantial and irreparable harm for which there is no adequate remedy at law” if the court allows a generic version of Tecfidera to be marketed right now.

MS Views and News is MAKING an IMPACT for those, affected by Multiple Sclerosis
MS Views and News provides beneficial Multiple Sclerosis education, information, resources and services. 
Join us, opt-in here: www.register.msviewsandnews.org 
..............................

No comments: